Literature DB >> 26169024

Screening Pools of Compounds against Multiple Endogenously Expressed Targets in a Chemoproteomics Binding Assay.

Elsa Salzer1, Elizabeth Nixon2, Gerard Drewes1, Friedrich Reinhard1, Giovanna Bergamini1, Christina Rau3.   

Abstract

Chemoproteomics-based competition-binding assays allow the screening of compounds against endogenous proteins in cell or tissue extracts, but these assays are hampered by low throughput and high cost. Using compound pools rather than single compounds in a screening campaign holds the promise of increased efficiency and substantial cost reduction. Previous attempts to screen compounds in pools often fell short due to complex data tracking, deconvolution issues, compound interferences, and automation problems. The desire to screen compounds in a high-throughput chemoproteomics format sparked a reassessment of compound pooling. Through the integration of acoustic dispensing, we enabled a flexible pooling process, allowing mixture creation by combining randomized or specific samples to create defined pools. Automation enabled end-to-end tracking, using barcode scan check points and output files to track data and ensure integrity during the mixture creation process. The compound pooling approach proved to be highly compatible with the chemoproteomics assay technology. Pools of 10 compounds in a single well did not show compound interference effects or increased false-positive/negative rates. In the present study, four targets, TBK1, PI3Kδ, PI3Kγ, and mTOR, were screened using a chemoproteomics approach against pools of 10 compounds per well, resulting in robust hit identification.
© 2015 Society for Laboratory Automation and Screening.

Entities:  

Keywords:  acoustic dispenser; chemoproteomics; compound pooling; high-throughput screening (HTS)

Mesh:

Substances:

Year:  2015        PMID: 26169024     DOI: 10.1177/2211068215595355

Source DB:  PubMed          Journal:  J Lab Autom        ISSN: 2211-0682


  2 in total

1.  Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells.

Authors:  H Christian Eberl; Thilo Werner; Friedrich B Reinhard; Stephanie Lehmann; Douglas Thomson; Peiling Chen; Cunyu Zhang; Christina Rau; Marcel Muelbaier; Gerard Drewes; David Drewry; Marcus Bantscheff
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

2.  Tests in short supply? Try group testing.

Authors:  Christopher R Bilder; Peter C Iwen; Baha Abdalhamid; Joshua M Tebbs; Christopher S McMahan
Journal:  Signif (Oxf)       Date:  2020-05-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.